Prescription practices and medical knowledge on direct oral anticoagulants in a reference hospital
DOI:
https://doi.org/10.17533/udea.iatreia.v28n2a05Keywords:
anticoagulants, knowledge, prescriptionAbstract
Introduction and objective: The experience and knowledge concerning the use of direct oral anticoagulants among specialists in Medellin, Colombia, are not known. Our goal was to describe the use of these drugs in patients treated at Hospital Pablo Tobón Uribe and to assess the level of knowledge regarding this issue in professionals from this institution.
Materials and methods: Cross sectional study conducted between January 2012 and January 2013. Two strategies to collect information were used, namely: Analysis of relevant medical records and evaluation of knowledge about the appropriate use and prescription of direct oral anticoagulants in the group of medical specialists.
Results: 114 records were included in the analysis; rivaroxaban was the most frequently prescribed drug (87%) followed by dabigatran (13%). The main indication was prophylaxis in orthopedic surgery (69%). Average of correct answers among the different specialists evaluated was 67% with no apparent difference between them.
Conclusion: rivaroxaban was prescribed more often than dabigatran; however, this fact does not appear to be associated with a clear and sufficient medical knowledge about these drugs. No reports of adverse events associated with this therapy were found.
Downloads
References
(1.) Navarro JL, Cesar JM, Fernández MA, Fontcuberta J, Reverter JC, Gol- Freixa J. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral. Rev Esp Cardiol. 2007 Dec;60(12):1226-32.
(2.) Smythe MA. Advances in anticoagulation management: the role of pharmacy. Ann Pharmacother. 2007 Mar;41(3):493-5.
(3.) Food and Drug Administration. Medication Guide: Xarelto® (Zah-REL- toe) (rivaroxaban) tablets. Reference ID: 3353958 [Internet]. Available from: http://pdf.thepdfportal.net/?id=93414
(4.) Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009 Jan;48(1):1-22.
(5.) European Medicines Agency. EPAR summary for the public: pradaxa, dabigatran etexilate (EMA/544606/2012) [Internet]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf
(6.) Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Rev Esp Cardiol Supl. 2013 Jan;13(C):33-41.
(7.) Aguilera B, Echeverri A, Palacio JC, Stangl W, Villa J, Cortés M. Efectos adversos de la terapia antitrombótica en reemplazos articulares, Rev colomb ortop traumatol. 2011 Jun; 25(2):243-7.
(8.) Pantaleón O, Triana M, Garrido M, Ríos M, Sánchez T. Estado actual en Cuba del control del tratamiento con anticoagulantes orales. Rev Cubana Angiol y Cir Vasc [Internet]. 2011; 12(1). Disponible en: http://www.bvs.sld.cu/revistas/ang/vol12_01_11/ang05111.htm
(9.) Huang C, Siu M, Vu L, Wong S, Shin J. Factors influencing doctors’ selection of dabigatran in nonvalvular atrial fibrillation. J Eval Clin Pract. 2013 Oct;19(5):938-43.
(10.) Carley B, Griesbach S, Larson T, Krueger K. Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting. Am J Cardiol. 2014 Feb;113(4):650-4.
(11.) Arribalzaga K, Asenjo S, Cesar JM, Llamas P, Oña F, Rodriguez AM, et al. Guía de uso de dabigatrán etexilato (Pradaxa®) en la prevención del ictus y embolismo sistémico en los pacientes con fibrilación auricular no valvular y otros factores de riesgo [Inter-net]. Madrid: Asociación Madrileña de hematología y hemoterapia; 2012 [consultado 2014 Ago]. Disponible en: http://www.hematologiamadrid.org/pdf/Con-senso_Dabigatran.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Iatreia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
